/NOT FOR DISTRIBUTION IN THE UNITED STATES OR THROUGH UNITED STATES WIRE
SERVICES/

TORONTO, March 25, 2014 /CNW/ - Biosign Technologies Inc. (TSXV: BIO)
("Biosign" or the "Company") is pleased to provide an update for
shareholders and announcements on the following subjects:

STRATEGY

In December 2013 Biosign announced the acquisition of two complimentary,
revenue producing software companies, IBL Internet Business Logic Inc.,
a pioneer in cloud-based clinic management software and QLINE Solutions
Inc., a leading supplier of enterprise software for the home care
industry. The Company also announced its largest-ever software sale, a
combined $6 million package divided into a one-time $3 million license
fee and a separate $3 million services agreement. These transactions
have now closed, and Biosign is pleased to describe the strategy
underpinning our activities.

Capitalizing on Opportunities for Rapid Growth:

After extensive research, the Company has concluded that the primary
unmet need in the markets we serve is the urgent requirement to connect
those in need of care with service providers who deliver care using new
cloud-based software solutions. For example, a typical clinic uses
paper-based forms and labour intensive practices to schedule
appointments, resulting in waste and inefficiency. At the same time,
clients have no easy online access to information about the care they
receive. Since our software is effective in streamlining the internal
management of clinics, Biosign is in the unique position to connect
customers to their healthcare providers in a convenient, seamless way.

The Company is pursuing two parallel paths to growth: we are creating
innovative proprietary solutions that disrupt incumbent players and at
the same time we are acquiring synergistic assets that increase
speed-to-market and deliver profits. Biosign continues to execute both
these strategies by improving our patent-pending Pulsewave® technology while simultaneously integrating QCARE & ClinicServer with
additional assets into a unique and compelling platform.

Under this strategy Biosign is participating in the Qualcomm Tricorder
XPRIZE competition, a $10 million innovation contest to develop a Star
Trek-like software system to record all 5 vital signs and independently
diagnose 15 separate diseases. A 2012 study by Parks Associates ("Digitally Fit: Healthy Living and Connected Devices") predicts that more than 32 million US consumers will actively track
their health & fitness online by 2016, up from about 15 million in 2011
(~100% growth). Revenue from online / mobile wellness service adoption
will increase from $337 million in 2011 to more than $2.4 billion by
2016 (~700% growth), according to the study.

Qualcomm Tricorder XPRIZE Competition

Biosign is pleased to report that we continue to be recognized as a
strong competitor in the Tricorder XPRIZE competition. On March 13th 2014 Biosign was featured on the technology blog io9, part of the
Gawker media platform. Gawker media has over 20 million unique visitors
to its media sites per month. Out of 34 teams competing in the XPRIZE,
5 were featured by io9, and first up was Biosign. We believe Biosign's
XPRIZE entry, consisting of our Pulsewave® MAX system married to a unique new invitro diagnostic (IVD) reader is
on track to reach our immediate goal to qualify as a finalist in August
2014. It is anticipated that the winner of the Tricorder XPRIZE, to be
announced in 2015, will be in a position to assume a leading position
in the market for consumer-friendly online health platforms from 2016
onward. View the interview at http://io9.com.

Gaining the Edge through Market Coverage

Biosign management is positioning the Company for increased growth by
ensuring market coverage in three inter-related ways:

a)

Geographical coverage, pursuing customers and partners with clinic or
home care locations across Canada, the United States and Europe;

b)

Vertical coverage, delivering solutions to be used simultaneously by
both consumers and care providers; and

c)

Longitudinal coverage, for example by providing solutions that connect
seniors with family caregivers and then later, connecting those same
seniors with approved home care providers, bridging the gap between
where family care leaves off and state / insurance funded home care
kicks in.

MATERIAL ANNOUNCEMENTS

Changes to the Board:

Biosign welcomes three new members to its Board of Directors, two of
whom were elected at the Annual General Meeting held on February 6th, 2014, and the third who has been appointed more recently:

Mr. Brian Neill is the current chairman of the board of Populus, a
provider of Healthcare Information Systems and previous founder &
chairman of public company Star Choice Communications Inc. Mr. Neill
had a successful legal career and was appointed to the Queens Council
in 1990. Mr. Neill was elected at the AGM.

Mr. John-Peter Bradford is founding Partner of Bradford Bachinski
Limited. An experienced CEO and board member, and senior business and
corporate finance advisor, he is a published scientist, and a Certified
Management Consultant (Fellow), who holds a B.A (Psychology) from
Fairfield University in Connecticut, an M.A. (Experimental Psychology)
from University of Toronto and a Ph.D. (Psychology and Community
Services) from Columbia Pacific University. Mr. Bradford was elected at
the AGM.

Mr. Tony Melles is the President of Achieva Health, an Ontario based
operator of Allied Health clinics, and former founder and President of
Canadian Back Institute (now CBI). Mr. Melles agreed to join the Board
effective February 15, 2014.

The Board and Management of Biosign would like to thank previous Board
members, Dr Sonny Kohli and former Chairman Mr. John Rizvi, for their
exemplary service. We are pleased to note that both previous directors
will continue to work with Biosign: Dr Kohli has accepted the position
of Chief Medical Officer with the Company, while Mr. Rizvi has accepted
the position of Managing Director, Middle East & Asia, where he will
assist the Company with recently announced distribution relationships
in that region. For complete biographies of the Company's managers,
directors and advisors please refer to www.biosign.com.

Biosign has executed a Resale & Internal Use Software License Agreement
with a leading software solutions provider in the insurance claims
management industry. This non-exclusive, fully paid-up North American
license allows the Company to utilize as well as resell a unique claims
management platform, coupled to Biosign's healthcare solutions
including ClinicServer and QCARE. Under a Professional Services &
Support Agreement, the licensor agreed to support Biosign in the
integration, setup and maintenance of the solution. Biosign paid $5
million for the license fee and $3 million for professional services,
in cash.

The Company intends to deploy this licensed solution to create a unique
service that automates the processing and delivery of allied health
benefit claims from insurance companies. For example, by integrating
employee benefit claims assessment data with our ClinicServer
physiotherapy clinic management solution, Biosign can deliver customers
directly to over 250 ClinicServer operators across Canada, making our
software even more compelling. In doing so, we will earn a transaction
fee for each claim delivered to a clinic within the ClinicServer
network. Biosign intends to have the initial iteration of this
automated solution ready for testing by the third quarter of 2014,

Financing for Growth:

Biosign has secured $4.75 million in debt financing in the form of a
Demand Loan Agreement (the "Loan") with interest payable at Bank of
England prime rate plus 3% per annum and no set repayment term. The
Loan is unsecured and use of funds for the principal of this Loan
include $2 million paid towards the Software License & Maintenance
Agreement mentioned above and $2.75 million for working capital.
Biosign is currently in discussion with potential strategic partners
regarding an equity placement, which we expect to price at a premium
over the market share price. These funds will be used for new product
development including XPRIZE, the automated benefits assessment
platform, and working capital needed to expand into available markets
quickly.

Conversion of Outstanding Indebtedness and Loans to Various Parties:

Biosign announced that upon approval of the TSX Venture Exchange it has
completed the share for debt transaction previously announced on
December 23, 2013 by issuing 3,147,305 common shares of the company in
settlement of $157,720.25 in outstanding debt. The issued common shares
will be restricted from sale for a period of 4 months and 1 day.
Meanwhile, Biosign has agreed to lend $166,725 to an officer of the
Company, and $132,000 to a consultant to the Company, on the following
terms: interest will be assessed at the Bank of Canada prime rate plus
2% per annum, and the full balance will be repaid within 12 months.

General Comments:

Biosign CEO Robert Kaul stated: "The ideas and events discussed in this
press release are quite informative for investors. First we described
our strategy for success, focusing on connecting people who need care
with those who provide it in three compelling ways - geographically,
within market verticals and across market categories. Next we reported
increased media recognition of Biosign as a technology innovator
including our status as a serious XPRIZE competitor. Like other
fast-growth technology companies we confirmed our intention to disrupt
incumbents with our proprietary Pulsewave® software while simultaneously acquiring synergistic assets & customers.
Along those lines we reported the acquisition of a software asset that
facilitates our ability to connect employee benefit claims with our
network of allied health clinics running ClinicServer, leading to a new
stream of transactional revenue by the end of 2014. We announced the
addition of 3 thought-leaders to our board, and welcomed former board
members to new roles in the Company. Finally, in our efforts to reduce
shareholder dilution we secured $4.75 million in low-cost, unsecured
debt and positioned future strategic equity financing to be at a
premium to our market price. These steps all share a common theme:
Biosign's strategy is to focus on our unique ability to deliver
accurate cloud-based solutions that connect multiple parties. By doing
so we work to gain media recognition, attract financing on improved
terms and realize customer and revenue growth, thereby delivering on
our promise of improved returns to shareholders."

About Biosign Technologies Inc.

Biosign Technologies Inc. (TSXV: BIO) provides automated,
software-enabled health information solutions including the Pulsewave® Health Monitor, Healthanywhere™ Patient monitoring platform,
ClinicServer™ clinic management software and QCARE™ enterprise
solutions for home care. The Company also offers a number of
cardiovascular screening programs for consumers under its Heart
Friendly™ brand. For more information on Biosign, please visit www.biosign.com

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking
statements, without limitation, may contain the words believes,
expects, anticipates, estimates, intends, plans, or similar
expressions. Forward-looking statements are not guarantees of future
performance. They involve risks, uncertainties and assumptions and
Biosign's actual results could differ materially from those
anticipated. Forward looking statements are based on the opinions and
estimates of management at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from those
projected in the forward-looking statements. In the context of any
forward-looking information please refer to risk factors detailed in,
as well as other information contained in the company's filings with
Canadian securities regulators (www.sedar.com).

Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.